Navigation Links
In blood vessel stents, innovative materials allow better control, delivery of gene therapy
Date:4/15/2008

Before gene therapy becomes practical for treating human diseases, researchers must master the details of safe and effective delivery. Cardiology researchers at The Childrens Hospital of Philadelphia have advanced delivery techniques by creating a versatile synthetic material that can bind to a variety of gene therapy vectors and can be custom-designed for controlled local release of therapeutic genes at a disease site.

In an animal study, the research team used their new synthetic formulation to bind adenoviruses to bare metal stents, tiny metal scaffolds inside the carotid arteries of rats. Adenovirus served as a gene therapy vector to carry genes for an enzyme that significantly reduced restenosis, the hazardous narrowing of a blood vessel that often occurs despite the presence of a stent designed to hold it open.

Although the materials are in an early stage, the hope is that this method may help to treat artery disease in people. We developed a synthetic gene delivery system that can be used for any gene therapy vector, not just adenoviruses, said study leader Robert J. Levy, M.D., the William J. Rashkind Chair of Pediatric Cardiology at The Childrens Hospital of Philadelphia. Furthermore, this new formulation allows us to increase the dosage of gene therapy vectors delivered, and we can tune the materials for sustained release over a longer time period.

Levys group reported its study this week in the online version of the journal Circulation, published by the American Heart Association.

Over the past decade, stents have become increasingly useful in treating constricted blood vessels in heart disease and in peripheral artery disease. Stents, which expand partially blocked blood vessels to improve circulation, may be made of bare metal or may have a coating of polymers that release drugs.

Neither type is ideal. Polymer coatings cause inflammation in vessels, which may lead to new bottlenecks at the same time th
'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Mediware Introduces Comprehensive Vision for Blood Center Technology
2. High Blood Pressure May Be Buffer Against Headaches
3. Potential blood test for chronic sinusitis identified
4. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
5. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
6. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
7. Blood vessels: The pied piper for growing nerve cells
8. Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes
9. Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit
10. Microwave treatments for enlarged prostate cause blood pressure surges
11. Blood pressure enzyme can have tumor-sensing role
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Westlake Village, CA (PRWEB) September 23, 2014 ... Sedation Dental Office is now offering complimentary oral sedation ... about 15 percent of Americans suffer from dental anxiety ... merely uncomfortable for patients; they can also keep patients ... dental anxiety or phobia in Westlake Village and surrounding ...
(Date:9/23/2014)... September 23, 2014 PM360, a leading ... the pharmaceutical industry with their annual Trailblazer Awards on ... gala banquet at Gotham Hall in New York City, ... representing top talent and brands. , ... says Anna Stashower, CEO and Publisher of PM360. “We ...
(Date:9/23/2014)... 23, 2014 Kenall Manufacturing, a ... its MedMaster™ M4 product line with a new ... M4 product line – currently available with 2'×2' ... providing more flexibility when designing lighting for the ... M4 Series include:, •Three sizes available to ...
(Date:9/23/2014)... Rockville, MD (PRWEB) September 23, 2014 ... a proposal by the World Health Organization (WHO) regarding ... , USP supports the effort by the Expert Group ... develop a consensus-based global approach to the naming of ... principles critical to the quality assessment of these drugs. ...
(Date:9/23/2014)... 2014 Catalent Pharma Solutions, ... technologies and development solutions for drugs, biologics ... it had reached an exclusive development and ... Cingulate Therapeutics (CTx), to support the development ... products for the treatment of Attention Deficit/Hyperactivity ...
Breaking Medicine News(10 mins):Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3
... HOUSTON - A $4 million, five-year grant from the ... Networks Program Center (CNPC), called Latinos Contra El Cancer, ... The center is a joint project of The ... School of Public Health and The University of Texas ...
... low-dose radiation from cardiac imaging and other procedures after ... of cancer, found a new study published in ... link only) http://www.cmaj.ca/embargo/cmaj100463.pdf . The use of ... (CT) angiography and nuclear scans, is increasing which has ...
... of Sweden decided to introduce a special blessing for ... making a distinction between genuine homosexuality and promiscuous homosexuality, ... a new thesis in religious studies at the University ... between opponents and supporters of the decision. "It ...
... rates continue to rise, University of Missouri researchers are ... an effective and inexpensive way for people with addictive ... Matthew Martens, associate professor of Educational, School and Counseling ... team of researchers received a $172,500 grant from ...
... produced by the DNA of tumor cells, researchers have ... new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists ... of a drug that blocks the protein,s activity. ... target for high-risk neuroblastoma," said pediatric oncologist Kristina A. ...
... two new works, an anthropologist tackles a perplexing question relating ... tolerate and even celebrate the public display of ... of Real Human Bodies " is the most widely attended ... professor of anthropology at the University of Illinois and author ...
Cached Medicine News:Health News:Project connects researchers, Latino communities to prevent cancer 2Health News:Project connects researchers, Latino communities to prevent cancer 3Health News:Risk of cancer increases with exposure to low-dose radiation 2Health News:Supporters and opponents of a special blessing for homosexuals share many values 2Health News:Simple feedback could be effective therapy for addictive behaviors 2Health News:Protein may be key to new treatment in a childhood cancer 2Health News:Protein may be key to new treatment in a childhood cancer 3Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 2Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 3
(Date:9/23/2014)... , Sept. 23, 2014 Today, DripDrop, the ... the formation of the DripDrop Foundation, with its ... dehydration worldwide. Utilizing scientific advancements in Oral Rehydration ... to reduce dehydration and healthcare costs through strategic ... "DripDrop has been used in ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... new additions to its Scientific Advisory Board.  The new ... Anthony Davies , PhD. Dr. Acker is ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
Breaking Medicine Technology:DripDrop Forms Foundation To Scale Relief Efforts 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5
... Adeona Pharmaceuticals, Inc. (AMEX: ... for serious central nervous system diseases, announced today ... the randomized, double-blind, placebo-controlled, multi-center clinical trial of ... multiple sclerosis (MS) in women, per the original ...
... MARLBOROUGH, Mass., Sept. 19, 2011 Advanced Cell Technology, ... of regenerative medicine, announced today that it has been ... the Company,s proprietary method for generating and expanding hemangioblast ... an exclusive license to commercialize the patented technology in ...
Cached Medicine Technology:Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 2Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 3Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 4Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 5ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 2ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 3ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
Medicine Products: